Overview

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

Status:
NOT_YET_RECRUITING

Trial end date:
2025-08-31

Target enrollment:

Participant gender:

Summary

Evaluating Pharmacokinetic and safety of Saroglitazar Magnesium 1 mg when dosed on alternate days in subjects having moderate hepatic impairment with cirrhosis due to cholestatic liver disease

Phase:

PHASE1

Details

Lead Sponsor:

Zydus Therapeutics Inc.

Treatments:

saroglitazar